Structural characteristics and SARs of EZH2 inhibitors
Molecular Diversity · 01.07.2025 · 30 (5) · 6499-6529
DOI: 10.1007/s11030-025-11272-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diversity, online erschienen am 01.07.2025. Verfasst von Ruosong Qin und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy of Liaoning University, API Engineering Technology Research Center of Liaoning Province, Small Molecular Targeted Drug R&D Engine…. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 137 Literaturangaben. Gefördert von: Basic Scientific Research Projects for Universities of Liaoning Provincial Department of Education, General Projects of Education Department of Liaoning Province, Shenyang Natural Science Foundation of Key Laboratory.
Abstract (Originalsprache)
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 (PRC2), plays a central role in the post-translational methylation of histone H3 lysine 27 (H3K27me3), thereby regulating gene silencing. Extensive studies have demonstrated that EZH2 is frequently overexpressed in a broad range of malignancies, where it promotes tumorigenesis and progression. Elevated EZH2 expression is strongly associated with increased tumor cell proliferation, invasion, metastasis, therapeutic resistance, higher tumor grade, and poor clinical outcomes. Currently, two EZH2 inhibitors have received regulatory approval for the treatment of cancers such as lymphoma, and both have shown clinical benefit in patients with relapsed or refractory disease. In this review, we provided a systematic analysis of recent advances in EZH2 inhibitor development, with a particular emphasis on classification based on core structural scaffolds. We highlighted the structure-activity relationships (SARs), pharmacological profiles, and the respective advantages and limitations of representative compounds in preclinical development. These insights were intended to offer the design of next-generation EZH2 inhibitors with improved selectivity, safety, and translational potential for targeted cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy of Liaoning University, API Engineering Technology Research Center of Liaoning Province, Small Molecular Targeted Drug R&D Engineering Research Center of Liaoning Province, Shenyang, 110036, Liaoning…
- School of Pharmacy, North China University of Science and Technology, Tangshan, 063210, Hebei, People's Republic of China.
Förderung
- Basic Scientific Research Projects for Universities of Liaoning Provincial Department of Education
- General Projects of Education Department of Liaoning Province
- Shenyang Natural Science Foundation of Key Laboratory
Zitieren
APA
Qin, R., Ma, B., Mou, S., Yuan, M., Xing, J., Shen, J., Ding, S., Chen, Y., & Liu, J. (2025). Structural characteristics and SARs of EZH2 inhibitors. Molecular Diversity, 30(5), 6499-6529. https://doi.org/10.1007/s11030-025-11272-w
Vancouver
Qin R, Ma B, Mou S, Yuan M, Xing J, Shen J, et al. Structural characteristics and SARs of EZH2 inhibitors. Molecular Diversity. 2025;30(5):6499-6529. doi:10.1007/s11030-025-11272-w
BibTeX
@article{Qin2025,
author = {Qin, Ruosong and Ma, Baohong and Mou, Shuo and Yuan, Mengwen and Xing, Jiahe and Shen, Jiwei and Ding, Shi and Chen, Ye and Liu, Ju},
title = {Structural characteristics and SARs of EZH2 inhibitors},
journal = {Molecular Diversity},
year = {2025},
volume = {30},
number = {5},
pages = {6499--6529},
doi = {10.1007/s11030-025-11272-w}
}
EUVIMED